Cargando…
Characterization of the Early Humoral and Cellular Response Developed in Oncohematological Patients Post-Vaccination with One Dose Against COVID-19
Background: Oncohematological patients present a variable immune response against many vaccines, due to the immunodeficiency caused by the disease and its treatment. The experience of vaccination against COVID-19 in oncohematological patients is low and mostly limited to studies of humoral immunity....
Autores principales: | Corona De Lapuerta, Magdalena, Rodriguez-Mora, Sara, Casado-Fernandez, Guiomar, Garcia-Pérez, Javier, Vigon, Lorena, Murciano-Antón, María Aranzazú, Blanchard, María Jesús, Marquet Palomanes, Juan, Martin Moro, Fernando, Palomo Rumschisky, Pablo, Pérez-Olmeida, Mayte, López Jiménez, Javier, López-Huertas, Maria Rosa, Coiras, Maria Teresa, Garcia Gutierrez, Valentín |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701633/ http://dx.doi.org/10.1182/blood-2021-152943 |
Ejemplares similares
-
Early Immune Profile Assessment By Flow Cytometry Predicts Severe COVID-19 Pneumonia
por: Rial-Villavecchia, Abora, et al.
Publicado: (2021) -
Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021) -
Lymphocyte Ratios Progressively Worsen in Non-Survivors of COVID-19
por: Alagbe, Adekunle Emmanuel, et al.
Publicado: (2021) -
A Multicompartment Mathematical Model Based on Host Immunity for Dissecting COVID-19 Heterogeneity
por: Wu, Jianghua, et al.
Publicado: (2021) -
Vaccine Efficacy after Rituximab Exposure: First Interim Analysis of Virtue Project on Behalf of West Midlands Research Consortium, UK
por: Shields, Adrian M, et al.
Publicado: (2021)